港股異動 | 樂普生物(2157.HK)高開近4% 康諾亞及樂普生物合營企業與AstraZeneca就CMG901訂立獨家許可協議
格隆匯2月23日丨樂普生物(2157.HK)高開近4%,報7港元,總市值116億港元。該公司今日公吿,KYM Biosciences Inc.(一家由集團與康諾亞成立的合營企業)與AstraZeneca AB(一家全球製藥公司)已訂立全球獨家許可協議,以開發及商業化集團與康諾亞通過KYM共同開發的候選藥物CMG901。根據許可協議並在其條款及條件的規限下,KYM將收取6300萬美元的預付款,並在達成若干開發、監管及商業里程碑後,收取最多11.25億美元的額外潛在付款。此外,KYM有權從AstraZeneca收取銷售淨額的分級特許權使用費。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.